No parental origin bias for the rearranged chromosomes in myeloid leukemias associated with t(9;22), t(8;21) and t(15;17).

abstract：:Imatinib mesylate, a Bcr/Abl tyrosine kinase inhibitor, is widely used in treating chronic myeloid leukemia. However, drug-resistance of leukemia cells becomes an emergent problem. Herein, various flavonoids were screened for applicability in leukemia treatment, and 3-hydroxyflavone (3-HF) was found to be most effecti...

journal_title：Leukemia research

authors： Kim JH,Song M,Kang GH,Lee ER,Choi HY,Lee C,Kim JH,Kim Y,Koo BN,Cho SG

更新日期：2012-09-01 00:00:00

abstract：:Vinorelbine chemotherapy with G-CSF stimulation is the standard mobilization regimen in Switzerland for multiple myeloma patients. However, with the increasing use of bortezomib during induction treatment, adding the neurotoxic compound vinorelbine for mobilization may aggravate bortezomib-induced polyneuropathy. In t...

journal_title：Leukemia research

authors： Keller S,Seipel K,Novak U,Mueller BU,Taleghani BM,Leibundgut K,Pabst T

更新日期：2015-07-01 00:00:00

abstract：:CD200 is a relatively ubiquitously expressed molecule that plays a role in cancer immune evasion through interaction with its receptors. High expression levels of CD200 have been described in different human malignancies. For example, CD200 has been shown to be targeted after RAS/RAF/MEK/ERK activation in melanoma. He...

journal_title：Leukemia research

authors： Conticello C,Giuffrida R,Parrinello N,Buccheri S,Adamo L,Sciuto MR,Colarossi C,Aiello E,Chiarenza A,Romano A,Salomone E,Gulisano M,Giustolisi R,Di Raimondo F

更新日期：2013-12-01 00:00:00

abstract：:The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5 months after discontinuation of IM. All 7 patients...

journal_title：Leukemia research

authors： Yhim HY,Lee NR,Song EK,Yim CY,Jeon SY,Shin S,Kim JA,Kim HS,Cho EH,Kwak JY

更新日期：2012-06-01 00:00:00

abstract：:Mutations in Janus kinase 2 (JAK2) are implicated in the pathogenesis of Philadelphia-chromosome negative myeloproliferative neoplasms, including primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Gandotinib (LY2784544), a potent inhibitor of JAK2 activity, shows increased potency for the JAK2V61...

journal_title：Leukemia research

authors： Verstovsek S,Mesa RA,Salama ME,Li L,Pitou C,Nunes FP,Price GL,Giles JL,D'Souza DN,Walgren RA,Prchal JT

更新日期：2017-10-01 00:00:00

abstract：:The etiology of LGL leukemia is not known; however, we recently detected HTLV-II in a patient with LGL leukemia. In this study, we found that sera from 6 of 28 patients with LGL leukemia were positive for HTLV-I/II using a whole virus ELISA; moreover, the ELISA-negative sera were near the positive cut-off value. There...

journal_title：Leukemia research

authors： Loughran TP Jr,Sherman MP,Ruscetti FW,Frey S,Coyle T,Montagna RA,Jones B,Starkebaum G,Poiesz BJ

更新日期：1994-06-01 00:00:00

abstract：:Dasatinib was approved for the treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients in first line therapy based on the demonstration of efficacy and safety reported in patients enrolled in clinical trials. We describe a multicentric Italian "real-life" experience of dasatinib used as frontline treat...

journal_title：Leukemia research

authors： Breccia M,Stagno F,Luciano L,Abruzzese E,Annunziata M,D'Adda M,Maggi A,Sgherza N,Russo-Rossi A,Pregno P,Castagnetti F,Iurlo A,Latagliata R,Cedrone M,Di Renzo N,Sorà F,Rege-Cambrin G,La Nasa G,Scortechini AR,Greco G

更新日期：2016-01-01 00:00:00

abstract：:We retrospectively analyzed allogenic stem cell transplantation (allo-SCT) outcomes in 82 patients with AML or MDS were conditioned with fludarabine, idarubicin, intravenous-busulfan and cytarabine (FIBA) or busulfan and cyclophosphamide (BuCy). Compared to BuCy regimen, reduced intensity conditioning (RIC) with FIBA ...

journal_title：Leukemia research

authors： Gao L,Gao L,Gong Y,Zhang C,Chen XH,Zhang X

更新日期：2013-11-01 00:00:00

abstract：:In 141 adult patients with diagnosis of acute myeloid leukemia the overall expression and intensity of expression of CD34 antigen on leukemic cells was investigated. Myeloid blasts were tested by applying direct immunofluorescence staining using anti-CD34 fluorescein monoclonal antibody in flow cytometry. CD34 antigen...

journal_title：Leukemia research

authors： Raspadori D,Lauria F,Ventura MA,Rondelli D,Visani G,de Vivo A,Tura S

更新日期：1997-07-01 00:00:00

abstract：:Normal human monocytes express Fas and are susceptible to Fas ligand (FasL)-induced apoptosis. Because the myeloid leukemia cell lines HL-60 and THP-1 can be differentiated into functional monocytes and macrophages, we studied their expression of Fas and Fas ligand (FasL) to determine whether there were differentiatio...

journal_title：Leukemia research

authors： Bremner TA,Chatterjee D,Han Z,Tsan MF,Wyche JH

更新日期：1999-10-01 00:00:00

abstract：:GNAS1 gene is located at the long arm of chromosome 20 (q13.32). GNAS1 gene deletion has never been investigated in MDS. A GNAS1 activating mutation (R201) was recently found in MDS. We applied FISH and DHPLC plus sequencing to investigate GNAS1 gene in MDS cases with and without del(20q) at karyotype. ...

journal_title：Leukemia research

authors： Di Giacomo D,Lema Fernandez AG,Pierini T,Crescenzi B,Brandimarte L,Matteucci C,Testoni N,Mecucci C

更新日期：2014-07-01 00:00:00

abstract：:Brazil is a wide country with huge contrasts. Its peculiarities can highlight environmental factors that could influence the frequencies of different cancers. The standard treatment and results achieved from several different areas of the country may not be found in others. The establishment of a national cooperative ...

journal_title：Leukemia research

authors： Lopes LF,Lorand-Metze I,Niero-Melo L,Tone LG,Velloso E,Campanaro CM,Latorre Mdo R

更新日期：2002-07-01 00:00:00

abstract：:Infant leukemia cells with 46XY,t(11; 17)(q23; p13) karyotype and a hybrid pre B myeloid phenotype (HLA-DR, (Ia), B4 and My7-positive and CALLA and T11-negative) and immunoglobulin heavy chain gene rearrangement were maintained in long-term culture for over 10 months. The in-vitro survival and growth of the leukemia c...

journal_title：Leukemia research

authors： Umiel T,Friedman S,Zaizov R,Cohen IJ,Gozes Y,Epstein N,Kobiler D,Zipori D

更新日期：1986-01-01 00:00:00

abstract：:A single somatic mutation, V617F, in the pseudokinase domain of the Jak2 is the primary cause of many chronic myeloproliferative diseases. As valine 617 of Jak2 is conserved as valine 678 of Tyk2, we examined the effect of a homologous mutation in Tyk2 (V678F Tyk2) on cell growth. V678F Tyk2 augmented the transcriptio...

journal_title：Leukemia research

authors： Shide K,Shimoda K,Kamezaki K,Kakumitsu H,Kumano T,Numata A,Ishikawa F,Takenaka K,Yamamoto K,Matsuda T,Harada M

更新日期：2007-08-01 00:00:00

abstract：:In 2008 the first evidence-based Canadian consensus guideline addressing the diagnosis, monitoring and management of transfusional iron overload in patients with myelodysplastic syndromes (MDS) was published. The Canadian Consortium on MDS, comprised of hematologists from across Canada with a clinical and academic int...

journal_title：Leukemia research

authors： Leitch HA,Buckstein R,Zhu N,Nevill TJ,Yee KWL,Leber B,Keating MM,St Hilaire E,Kumar R,Delage R,Geddes M,Storring JM,Shamy A,Elemary M,Wells RA

更新日期：2018-11-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a heterogeneous disease. Until recently, treatment for patients with AML was limited to induction chemotherapy with cytarabine and anthracycline or hypomethylating agents, and, in some instances, allogeneic hematopoietic stem cell transplant. With the recent approval of new therapies-i....

journal_title：Leukemia research

authors： Talati C,Sweet K

更新日期：2018-10-01 00:00:00

abstract：:The concurrent development of chronic myeloid (CML) or myelomonocytic (CMML) leukemia in patients with systemic mastocytosis (SM) is a well recognized phenomenon. Although the leukemia often resembles CML in morphological and in clinical terms, a Ph-Chromosome-positive variant has not been reported in SM so far. We he...

journal_title：Leukemia research

authors： Agis H,Sotlar K,Valent P,Horny HP

更新日期：2005-10-01 00:00:00

abstract：:2',5'-oligoadenylate synthetase (OAS) has been implicated in the effects of interferons (INF) and steroid hormones on cell growth and differentiation. We studied the combined effects in vitro of hormones and INF on OAS activity in cells from 10 patients with chronic lymphocytic leukemia. IFN enhanced OAS activity in a...

journal_title：Leukemia research

authors： Triozzi PL,Avery KB,Abou-Issa HM,Chou TC

更新日期：1989-01-01 00:00:00

abstract：:In this report we evaluated the exact expression pattern of c-Kit on mobilized peripheral blood (PB) CD34+ cells. Using a monoclonal antibody against CD117 antigen (95C3), flow cytometric analysis revealed that approximately 25% of the mobilized PB CD34+ cells coexpress c-Kit. This cell fraction showed a considerable ...

journal_title：Leukemia research

authors： Kuçi S,Taylor G,Neu S,Schumm M,Niethammer D,Handgretinger R

更新日期：1998-04-01 00:00:00

abstract：:This retrospective study of the thrombocythemia Italian registry (RIT) documented that 71 (30.6%) out of 232 ET patients experienced 88 cardiovascular adverse events (CV-AEs) during anagrelide treatment (522 pt-y). The rate of CV-AEs was: 24.1% for palpitations, 4.3% for angina, 3.5% for arterial hypertension, 3.0% fo...

journal_title：Leukemia research

authors： Gugliotta L,Tieghi A,Tortorella G,Scalzulli PR,Ciancia R,Lunghi M,Cacciola E,Cacciola R,Candoni A,Crugnola M,Codeluppi K,Usala E,Specchia G,Martinelli V,Palmieri F,Pierri I,Liberati AM,Iurlo A,Grossi A,Vannucchi AM

更新日期：2011-12-01 00:00:00

abstract：:CD200, a membrane glycoprotein of the immunoglobulin superfamily, is overexpressed in CLL. Soluble in serum CD200 (sCD200) is correlated with poor prognosis in CLL. ADAM (a disintegrin and metalloproteinase) enzymes are implicated in membrane protein shedding. ADAM28 mRNA expression in CLL was correlated with plasma s...

journal_title：Leukemia research

authors： Twito T,Chen Z,Khatri I,Wong K,Spaner D,Gorczynski R

更新日期：2013-07-01 00:00:00

abstract：:Recent studies have identified SOX11 as a novel diagnostic marker for mantle cell lymphoma (MCL). We quantified SOX11 by a truly mRNA specific qPCR assay in longitudinal peripheral blood samples from 20 patients and evidenced a close relationship of SOX11 expression and clinical status of the patients. In eight patien...

journal_title：Leukemia research

authors： Simonsen AT,Sørensen CD,Ebbesen LH,Bødker JS,Bentzen HH,Nyvold CG

更新日期：2014-08-01 00:00:00

abstract：:Despite initial remissions, most patients with Ph chromosome positive (Ph(+)) acute leukemia (AL) become refractory to tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib. This study was designed to determine if targeting the interleukin-3 receptor (IL-3R) with a diphtheria toxin fusion protein (DT(388)IL...

journal_title：Leukemia research

authors： Kim HP,Frankel AE,Hogge DE

更新日期：2010-08-01 00:00:00

abstract：:The present study explored the effects of Forkhead box Q1 (FOXQ1) on cell proliferation, cell cycle and apoptosis via the Sonic hedgehog (Shh) pathway in Natural killer/T-cell lymphoma (NKTCL). Quantitative real time-polymerase chain reaction (qRT-PCR) was performed to detect FOXQ1 expression in 117 NKTCL patients and...

journal_title：Leukemia research

authors： Liu P,Chen L

更新日期：2018-01-01 00:00:00

abstract：:Thirty patients with high-risk myelodysplastic syndrome, defined as > 5% bone marrow blasts, were treated with a combination of oral all-trans-retinoic acid (45 mg/m2 daily) and subcutaneous AraC (10 mg/m2) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles. Complete remission lasting 9, 12, and 15 months wa...

journal_title：Leukemia research

authors： Letendre L,Noel P,White WL,Tefferi A,Litzow MR,Li CY,Schroeder G

更新日期：1999-09-01 00:00:00

abstract：:The study was undertaken to elucidate the regulatory roles of GMP reductase (GMPR) and IMP dehydrogenase (IMPDH) on purine interconversion during differentiation. Treatment of HL-60 cells with retinoic acid (1 microM) induced granulocytic differentiation which was accompanied with a 2.4-fold increase in GMPR and 55% d...

journal_title：Leukemia research

authors： Nakamura H,Natsumeda Y,Nagai M,Takahara J,Irino S,Weber G

更新日期：1992-06-01 00:00:00

abstract：:The ubiquitin-proteasome pathway is implicated in the pathogenesis of many haematologic malignancies, including multiple myeloma. Under conditions of rapid cell turnover and growth rate, proteasomes are returned into circulation. The measurement of their levels or activity could offer a new approach to diagnosis, prog...

journal_title：Leukemia research

authors： Oldziej A,Bolkun L,Galar M,Kalita J,Ostrowska H,Romaniuk W,Kloczko J

更新日期：2014-08-01 00:00:00

abstract：:Of 597 cases of acute leukaemia in adults (greater than 16 years) seen at St. Bartholomew's Hospital, London, between May 1973 and January 1982, 412 were diagnosed as AML, 103 as ALL and 58 as Philadelphia chromosome positive blast crisis of CML (13 presenting as acute leukaemia and 45 having a prior chronic phase). T...

journal_title：Leukemia research

authors： Greaves MF,Bell R,Amess J,Lister TA

更新日期：1983-01-01 00:00:00

abstract：:T-cell leukemias were induced in adult BDF1 mice by a single i.v. injection of methylnitrosourea (MNU). Leukemogenesis was delayed by a single or repeated injections of hydrocortisone (HC) after MNU and also when HC was given one day before MNU. Enhancement of leukemogenesis was seen in experiments with 10 and 14 days...

journal_title：Leukemia research

authors： Seidel HJ,Kreja L

更新日期：1985-01-01 00:00:00

abstract：:Recently, we identified a novel chromosomal rearrangement in Hodgkin lymphoma (HL), t(4;8)(q27;q24), which targets homeobox gene ZHX2 at the recurrent breakpoint 8q24. This aberration deletes the far upstream region of ZHX2 and results in silenced transcription pinpointing loss of activatory elements. Here, we have lo...

journal_title：Leukemia research

authors： Nagel S,Schneider B,Meyer C,Kaufmann M,Drexler HG,Macleod RA

更新日期：2012-05-01 00:00:00